

Xyrem[®] (sodium oxybate) – First-time authorized brand alternative

- On January 3, 2023, <u>Hikma launched</u> an authorized brand alternative (ABA) of Jazz's <u>Xyrem</u> (sodium oxybate) oral solution.
 - Hikma will have 180 days of marketing exclusivity for its ABA product in the U.S.
- Xyrem is approved for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
- Xyrem carries a boxed warning for central nervous system depression, and abuse and misuse.
- Jazz reported net sales for Xyrem of \$1.3 billion in 2021.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.